Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients

Table 2

p190-13 peptide-specific CD4+ T cell proliferation obtained in 5 healthy donor (HD) and 6 Ph+ ALL patients (HD: healthy donor; SI: stimulation index; HR: hematologic remission).

	Age, sex	Disease stage	Current treatment	p190-13 CD4+ T cell SI
HD 1	58 M	—	—	2.0
HD 2	43 F	—	—	2.5
HD 3	55 M	—	—	2.3
HD 4	34 M	—	—	2.7
HD 5	52 F	—	—	2.3
Ph+ ALL 1	73 M	HR	dasatinib	1.0
Ph+ ALL 2	69 F	HR	dasatinib	1.0
Ph+ ALL 3	57 F	HR	dasatinib	2.2
Ph+ ALL 4	43 M	HR	imatinib	2.0
Ph+ ALL 5	64 F	HR	imatinib	2.2
Ph+ ALL 6	72 F	HR	imatinib	2.1